



(51) International Patent Classification:

A61P 25/26 (2006.01) C07D 519/00 (2006.01)

A61P 25/28 (2006.01) A61K 31/553 (2006.01)

(21) International Application Number:

PCT/JP2024/037121

(22) International Filing Date:

18 October 2024 (18.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023-180676 20 October 2023 (20.10.2023) JP



(71) Applicant: **TEIJIN PHARMA LIMITED** [JP/JP]; 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 1000013 (JP).(72) Inventors: **OKADA, Kazuhisa**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 1000013 (JP). **SASAKI, Kosuke**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 1000013 (JP).

ited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 1000013 (JP). **MUTOH, Hiroyuki**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 1000013 (JP). **KIMURA, Kumi**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 1000013 (JP). **SASAKI, Shouta**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 1000013 (JP). **SUZUKI, Shinji**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 1000013 (JP). **UMEDA, Koji**; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 1000013 (JP).

(74) Agent: **AOKI, Atsushi** et al.; SEIWA PATENT & LAW, Toranomon Hills Mori Tower, 23-1, Toranomon 1-chome, Minato-ku, Tokyo, 1050001 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(54) Title: CRYSTAL OF OXAZEPINE DERIVATIVE OR CRYSTAL OF SOLVATE THEREOF

**FIG.1**

(57) **Abstract:** [Problems] An object of the present invention is to provide a crystal of an oxazepine derivative or a crystal of a solvate thereof, which has excellent orexin type 2 receptor agonist activity and is useful for the prevention or treatment of, for example, narcolepsy, idiopathic hypersomnia, hypersomnia. [Solution] A crystal of a compound represented by the following formula (I): [in the formula (I), R¹ represents a methyl group or a methyl group substituted with 1 to 3 fluorine atoms; and R² and R³ each independently represent a hydrogen atom or a fluorine atom], or a crystal of a solvate of the compound represented by the formula (I). [Selected figure] Fig. 1

[Continued on next page]



HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))